Controlled Delivery of Nitric Oxide for Cancer Therapy

  • Alimoradi H
  • Greish K
  • Gamble A
  • et al.
102Citations
Citations of this article
92Readers
Mendeley users who have this article in their library.

Abstract

Nitric oxide (NO) is a short-lived, endogenously produced, signaling molecule which plays multiple roles in mammalian physiology. Underproduction of NO is associated with several pathological processes; hence a broad range of NO donors have emerged as potential therapeutics for cardiovascular and respiratory disorders, wound healing, the immune response to infection, and cancer. However, short half-lives, chemical reactivity, rapid systemic clearance, and cytotoxicity have hindered the clinical development of most low molecular weight NO donors. Hence, for controlled NO delivery, there has been extensive effort to design novel NO-releasing biomaterials for tumor targeting. This review covers the effects of NO in cancer biology, NO releasing moieties which can be used for NO delivery, and current advances in the design of NO releasing biomaterials focusing on their applications for tumor therapy.

Cite

CITATION STYLE

APA

Alimoradi, H., Greish, K., Gamble, A. B., & Giles, G. I. (2019). Controlled Delivery of Nitric Oxide for Cancer Therapy. Pharmaceutical Nanotechnology, 7(4), 279–303. https://doi.org/10.2174/2211738507666190429111306

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free